Anthrax Vaccine Market Size, Demand, Share and Trends to 2030

As demonstrated by Precision Business Insights (PBI), the latest report, the global Anthrax Vaccine Market was valued at USD 32.6 million in 2023 and is poised to grow at a CAGR of 3.1% from 2024-2030. The key drivers for the growth of the global Anthrax Vaccine market include bioterrorism threats, military necessity, heightened awareness, and technological advancements.

View Full Report: https://www.precisionbusinessinsights.com/market-reports/global-anthrax-vaccine-market

The Anthrax Vaccine Market Detailed Segmentation:
Based on the product type, the market is segmented into the following:
• Live Vaccine
• Sub Unit Vaccine

Based on distribution channel, the market is segmented into the following:
• Hospitals
• Defense & Military Centers
• Others

Based on the product type, the Anthrax Vaccine market is segmented into live vaccine and sub-unit vaccine. Among these, sub-unit vaccines are anticipated to account for a larger revenue share in the global Anthrax Vaccine market. In 2023, the subunit vaccine segment accounted for 99.5% revenue share and is projected to grow at 3.1% CAGR over 2024-2030 due to fewer side effects, safer for certain populations, and easier storage and handling. Advances in vaccine technology, particularly in recombinant DNA technology, are facilitating the development of more effective and targeted subunit anthrax vaccines. These advancements allow scientists to isolate and purify specific antigens that trigger a strong immune response against anthrax. As the focus of anthrax preparedness shifts from solely military use to potentially including broader public health initiatives, subunit vaccines with their milder side effects become more attractive. This could lead to increased demand for subunit vaccines in the future. In addition, regulatory bodies like the FDA might show greater openness to approving subunit vaccines due to their potentially improved safety profile. This could expedite the development and commercialization of new subunit vaccines. Moreover, the threat of anthrax being used as a bioweapon remains a concern. Subunit vaccines, with their potential for easier storage and distribution, could become a valuable tool for stockpiling and rapid response in the event of a bioterrorism attack. However, subunit vaccines may not always match the established efficacy of live attenuated spore vaccines. Further research and development are needed to ensure subunit vaccines offer a robust and long-lasting immune response against anthrax.

Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=231487

Based on the region, the market is segmented into the following
• North America
• Europe
• The Asia Pacific
• Latin America
• MEA

The global Anthrax Vaccine market, is currently led by North America. North America region currently holds the largest market share and a growing signifiantly due to government initiatives, strong military presence, advanced healthcare infrastructure, and established players. The USA Strategic National Stockpile used to purchase more than 9 million anthrax vaccines every year before 2016. After 2016, the USA procures only six million (2017-2021) of anthrax vaccines every year with a decrease in unit cost from USD 31 to 28 per dose. Earlier the government maintained close to 100 Million doses of anthrax vaccines till 2016. However, they have reduced the budget for the purchase of anthrax vaccines over the years which might have an impact on the stockpile data. The USA is one of the leading purchasers of the Anthrax vaccines across the globe. They have purchased/given contracts close to USD 4.4 billion worth of anthrax vaccines from Emergent BioSolutions from 2010 to 2024. The US government plays a proactive role, particularly through agencies like the Biomedical Advanced Research and Development Authority (BARDA), by funding research, development, and stockpiling of anthrax vaccines.

Request Methodology: https://www.precisionbusinessinsights.com/request-methodology/?product_id=231487

Strategic Expansion, Mergers, Collaborations, and Agreements are the key Strategies Adopted by Market Players:
In recent research, the Anthrax Vaccine market further divulges that the key players are intensively adopting strategies such as the launch of newer vaccines & drug, research and development in the Anthrax Vaccine and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance, In June 2022, US FDA granted review acceptance of the Biologics Permit Application (BLA) for AV7909 (Bacillus anthracis Immunization Adsorbed, Adjuvanted) for Emanant BioSolutions Inc. AV7909 is evaluated for post-exposure prophylaxis of illness following thought or contact openness to Bacillus anthracis in adults (age bunch 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

Key players profiles in the Anthrax Vaccine market are Altimmune, Panacea Biotec Limited, Porton Biopharma Limited, and Emergent BioSolutions Inc.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to delivering more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.